

April 25, 2012

To,
The Manager (Listing),
National Stock Exchange of India Ltd.,
"Exchange Plaza", G-1, Block G,
Bandra-Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir;

Re: Audited Financial Results for the Year ended on 31st March, 2012.

With reference to the captioned matter, we enclose herewith the Audited Financial Results of the Company for the Year ended on 31-March-2012, which were adopted by the Board of Directors of the Company at its meeting held today i.e. April 25, 2012.

The Board of Directors has recommended dividend Rs. 1.40 per Equity Share i.e. @ 70% on 18,85,15,914 Equity Shares of Rs.2/- each for the year ended on 31-March-2012.

We also send herewith press release dated April 25, 2012.

Kindly take note of the same.

Thanking you,

Yours faithfully,
For **Alembic Pharmaceuticals Limited**


R.K. Baheti
Director-Finance &
Company Secretary



Encl: A/a

₹ in lacs

		CONSOLIDATED				
Particulars		Quarter Ended on 31 st March 2012	Quarter Ended on 31 st December 2011	Quarter Ended on 31 st March 2011	Year Ended on 31 st March 2012	Year Ended on 31 st March 2011
PART- I		(Audited)	(Reviewed)	(Audited)	(Audited)	(Audited)
1	(a) Net Sales / Income from Operations					
	Domestic	20,373	21,720	18,956	87,718	78,805
	Exports	13,857	16,562	10,817	59,071	41,859
	Total	34,230	38,282	29,773	146,789	120,664
	Less : Excise Duty	151	149	126	554	766
	Net Sales / Income from Operations	34,079	38,133	29,647	146,235	119,898
	(b) Other Operating Income	182	79	85	404	306
Total Income from Operations		34,261	38,212	29,732	146,639	120,204
2	Expenses					
	(a) Decrease/(increase) in stock in trade and work in progress	(3,435)	250	1,613	(6,444)	(472)
	(b) Consumption of Raw Materials & Packing Materials	12,684	12,916	10,793	52,824	43,494
	(c) Purchase of traded goods	6,055	5,774	2,594	24,412	16,018
	(d) Employees' Cost	4,311	4,324	4,181	16,846	14,921
	(e) Research and Development Expense	2,214	976	1,574	5,858	4,714
	(f) Excise Duty	311	(37)	129	509	664
	(g) Other Expenditure	8,011	7,161	6,128	30,593	24,840
Total Expenses		30,149	31,364	27,012	124,597	104,179
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	4,111	6,848	2,720	22,041	16,025
4	Other Income	13	13	3	44	8
5	Profit/(Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	4,125	6,861	2,723	22,086	16,033
6	Depreciation	892	809	784	3,365	2,959
7	Interest (Net)	538	698	636	2,621	2,389
8	Net Profit / (Loss) from Ordinary Activities before Tax	2,694	5,354	1,303	16,099	10,685
9	Tax Expense					
	Less : Provision for Current Tax	526	964	51	3,123	1,864
	(Less)/Add : Provision for Deferred Tax (Liability)/Assets	137	(33)	224	(38)	282
10	Net Profit / (Loss) from Ordinary Activities after Tax	2,031	4,423	1,028	13,014	8,539
11	Paid up Equity Share Capital (Face value of share ₹ 2/-)	3,770	3,770	3,770	3,770	3,770
12	Reserves excluding Revaluation Reserve				35,730	25,903
13	Debenture Redemption Reserve				3,125	2,333
14	Basic & Diluted EPS (Not Annualised)	1.08	2.35	0.55	6.90	4.53
15	Debt Equity Ratio	-	-	-	0.94	1.25
16	Debt Service Coverage Ratio	-	-	-	3.06	2.26
17	Interest Service Coverage Ratio	-	-	-	12.40	9.41
PART- II						
A Particulars of Shareholding						
1	Public Shareholding					
	- Number of Shares	48763089	48763089	48763089	48763089	48763089
	- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding					
	- Fully Non - Encumbered					
	- Number of Shares	139752825	139752825	139752825	139752825	139752825
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13
B INVESTOR COMPLAINTS		Quarter ended on 31st March, 2012				
Pending at the beginning of the quarter		NIL				
Received during the quarter		2				
Disposed of during the quarter		2				
Remaining unresolved at the end of the quarter		NIL				



Notes :

- 1 The above results, which includes audited results of the Subsidiary, have been duly audited by Statutory Auditors, were recommended by the Audit Committee and were approved by Board of Directors. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement.
The Standalone Financial Results are available on the company's website www.alembic-india.com.
- 2 The Board has recommended dividend on Equity Shares at ₹ 1.40 per share i.e. 70% for the year ended on 31.03.2012
(PY ₹ 1/- per share i.e 50%)
- 3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 4 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Place : Vadodara
Date : 25th April, 2012



Visit us at www.alembic-india.com

For Alembic Pharmaceuticals Limited


Chirayu Amin
Chairman and Managing Director

Consolidated Statement of Assets and Liabilities

₹ in lacs

Particulars	As at 31st March, 2012	As at 31st March, 2011
A EQUITY AND LIABILITIES		
1 Shareholders' funds		
(a) Share capital	3,770.32	3,770.32
(b) Reserves and surplus	35,729.52	25,903.14
Sub-total - Shareholders' funds	39,499.84	29,673.46
2 Non-current liabilities		
(a) Long-term borrowings	9,485.67	12,848.37
(b) Deferred tax liabilities (net)	952.90	537.46
(c) Other long-term liabilities	1,229.07	1,184.17
(d) Long-term provisions	539.04	510.16
Sub-total - Non-current liabilities	12,206.69	15,080.16
3 Current liabilities		
(a) Short-term borrowings	13,945.77	14,627.68
(b) Trade payables	20,914.53	13,856.70
(c) Other current liabilities	15,057.24	8,490.05
(d) Short-term provisions	3,566.34	2,636.76
Sub-total - Current liabilities	53,483.88	39,611.20
TOTAL - EQUITY AND LIABILITIES	105,190.41	84,364.82
B ASSETS		
1 Non-current assets		
(a) Fixed assets	32,606.16	29,849.57
(b) Non-current investments	329.99	326.17
(c) Long-term loans and advances	3,499.13	654.47
Sub-total - Non-current assets	36,435.28	30,830.21
2 Current assets		
(a) Inventories	25,874.15	21,923.19
(b) Trade receivables	19,933.11	20,197.39
(c) Cash and Bank Balance	4,708.05	628.93
(d) Short-term loans and advances	18,239.82	10,785.10
Sub-total - Current assets	68,755.13	53,534.60
TOTAL - ASSETS	105,190.41	84,364.82



For Alembic Pharmaceuticals Limited

Chirayu Amin
Chairman and Managing Director

₹ in lacs

	Particulars	STANDALONE				
		Quarter Ended on 31 st March 2012	Quarter Ended on 31 st December 2011	Quarter Ended on 31 st March 2011	Year Ended on 31 st March 2012	Year Ended on 31 st March 2011
	PART- I	(Audited)	(Reviewed)	(Audited)	(Audited)	(Audited)
1	(a) Net Sales / Income from Operations					
	Domestic	20,373	21,720	18,956	87,718	78,805
	Exports	11,454	13,340	10,817	49,961	38,147
	Total	31,827	35,060	29,773	137,679	116,952
	Less : Excise Duty	151	149	126	554	766
	Net Sales / Income from Operations	31,676	34,911	29,647	137,125	116,186
	(b) Other Operating Income	182	79	85	404	306
	Total Income from Operations	31,857	34,990	29,732	137,528	116,492
2	Expenses					
	(a) Decrease/(increase) in stock in trade and work in progress	(3,435)	250	1,613	(6,444)	(472)
	(b) Consumption of Raw Materials & Packing Materials	12,684	12,916	10,793	52,824	43,494
	(c) Purchase of traded goods	4,110	3,272	2,594	16,779	12,857
	(d) Employees' Cost	4,311	4,324	4,181	16,846	14,921
	(e) Research and Development Expense	2,214	976	1,574	5,858	4,714
	(f) Excise Duty	311	(37)	129	509	664
	(g) Other Expenditure	7,712	7,263	6,232	30,200	24,740
	Total Expenses	27,906	28,964	27,117	116,571	100,919
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	3,951	6,026	2,615	20,957	15,573
4	Other Income	13	13	3	44	8
5	Profit/(Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	3,964	6,039	2,618	21,001	15,581
6	Depreciation	892	809	784	3,365	2,959
7	Interest (Net)	538	698	636	2,621	2,389
8	Net Profit / (Loss) from Ordinary Activities before Tax	2,534	4,532	1,198	15,015	10,233
9	Tax Expense					
	Less : Provision for Current Tax	508	864	23	3,000	1,801
	(Less)/Add : Provision for Deferred Tax (Liability)/Assets	137	(33)	224	(38)	282
10	Net Profit / (Loss) from Ordinary Activities after Tax	1,890	3,701	951	12,054	8,150
11	Paid up Equity Share Capital	3,770	3,770	3,770	3,770	3,770
	(Face value of share ₹ 2/-)					
12	Reserves excluding Revaluation Reserve				32,316	23,851
13	Debenture Redemption Reserve				3,125	2,333
14	Basic & Diluted EPS (Not Annualised)	1.00	1.96	0.50	6.39	4.32
15	Debt Equity Ratio	-	-	-	1.02	1.34
16	Debt Service Coverage Ratio	-	-	-	2.91	2.20
17	Interest Service Coverage Ratio	-	-	-	11.76	9.13
	PART- II					
A	Particulars of Shareholding					
1	Public Shareholding					
	- Number of Shares	48763089	48763089	48763089	48763089	48763089
	- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding					
	- Fully Non - Encumbered					
	- Number of Shares	139752825	139752825	139752825	139752825	139752825
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13
B	INVESTOR COMPLAINTS	Quarter ended on 31st March, 2012				
	Pending at the beginning of the quarter	NIL				
	Received during the quarter	2				
	Disposed of during the quarter	2				
	Remaining unresolved at the end of the quarter	NIL				



Notes :

- 1 The above results, which includes audited results of the Subsidiary, have been duly audited by Statutory Auditors, were recommended by the Audit Committee and were approved by Board of Directors. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement.
The Standalone Financial Results are available on the company's website www.alembic-india.com.
- 2 The Board has recommended dividend on Equity Shares at ₹ 1.40 per share i.e. 70% for the year ended on 31.03.2012
(PY ₹ 1/- per share i.e 50%)
- 3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 4 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Place : Vadodara
Date : 25th April, 2012



For Alembic Pharmaceuticals Limited

A handwritten signature in brown ink, appearing to be 'Chirayu Amin', with a long horizontal stroke extending to the right.

Chirayu Amin

Chairman and Managing Director

Visit us at www.alembic-india.com

Standalone Statement of Assets and Liabilities

₹ in lacs

Particulars	As at 31st March, 2012	As at 31st March, 2011
A EQUITY AND LIABILITIES		
1 Shareholders' funds		
(a) Share capital	3,770.32	3,770.32
(b) Reserves and surplus	32,315.92	23,850.64
Sub-total - Shareholders' funds	36,086.24	27,620.96
2 Non-current liabilities		
(a) Long-term borrowings	9,485.67	12,848.37
(b) Deferred tax liabilities (net)	952.90	537.46
(c) Other long-term liabilities	1,229.07	1,184.17
(d) Long-term provisions	539.04	510.16
Sub-total - Non-current liabilities	12,206.69	15,080.16
3 Current liabilities		
(a) Short-term borrowings	13,945.77	14,627.68
(b) Trade payables	18,192.75	13,175.41
(c) Other current liabilities	15,057.24	8,490.05
(d) Short-term provisions	3,566.34	2,590.85
Sub-total - Current liabilities	50,762.10	38,883.99
TOTAL - EQUITY AND LIABILITIES	99,055.02	81,585.11
B ASSETS		
1 Non-current assets		
(a) Fixed assets	32,605.83	29,848.84
(b) Non-current investments	335.42	335.42
(c) Long-term loans and advances	3,499.13	654.47
Sub-total - Non-current assets	36,440.38	30,838.73
2 Current assets		
(a) Inventories	25,874.15	21,923.19
(b) Trade receivables	18,683.28	20,197.39
(c) Cash and Bank Balance	2,572.47	128.80
(d) Short-term loans and advances	15,484.75	8,497.00
Sub-total - Current assets	62,614.65	50,746.38
TOTAL - ASSETS	99,055.02	81,585.11



For Alembic Pharmaceuticals Limited

Chiraya Amin
Chairman and Managing Director